Disitamab Vedotin Plus Mitomycin C for HER2-Positive Bladder Cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You had bladder cancer surgery (TURBT) with no obvious remaining tumors
- Your cancer is non-muscle-invasive (stays in the bladder lining) and is intermediate or high risk
- Your tumor tissue shows HER2 expression (a protein marker) on testing
- You cannot tolerate BCG treatment or prefer not to receive it
- You have no signs of cancer spread to lymph nodes or other organs on imaging
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
This trial tests a new targeted drug (disitamab vedotin) combined with immunotherapy against the standard chemotherapy-immunotherapy combination for muscle-invasive bladder cancer that expresses HER2 protein. The goal is to see if the new approach works better and is safer for patients before bladder removal surgery.
This trial tests a combination of targeted therapy (disitamab vedotin) and immunotherapy (tislelizumab) given before a repeat bladder scraping surgery (re-TURBT) for people with high-risk or very high-risk non-muscle invasive bladder cancer that has high levels of HER2 protein (2+ or 3+). The goal is to see if this approach is safe and helps reduce the chance of the cancer coming back.
This trial tests a combination of targeted therapy (Disitamab Vedotin), immunotherapy (PD-1 inhibitor), and radiation to help avoid bladder removal. It is for people with HER2-high muscle-invasive bladder cancer who have had a maximal transurethral resection (TURBT).
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
This study tests a combination of two drugs given directly into the bladder for a type of early-stage bladder cancer that has a specific protein marker called HER2. The goal is to see if the combination helps prevent the cancer from coming back.
Hear when a new Non-Muscle-Invasive Bladder Cancer (NMIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.